Business growth

Kadmon Holdings raised $50mn by selling 11.1mn shares at market price. The funds will be used to launch production and further promote Belumosudil, a drug that helps reduce the severity of symptoms of a chronic graft reaction against the host - a complication that develops after a stem cell or bone marrow transplant. It is planned to apply for registration as a drug in the 4th quarter of 2020.